About our research group/lab
Our research
Why was this group formed?
Together with prof. Rudi Hendriks, we investigate the role of T helper 17 cells in Chronic obstructive pulmonary diseases (COPD), Community-acquired pneumonia (CAP) and Cystic Fibrosis (CF). Together with the Amphia hospital in Breda, we have a research collaboration in the field of COPD exacerbations.
What is the overall aim?
We have performed an investigator initiated randomized placebo-controlled trial to the effects of azithromycin in prevention of COPD exacerbations. The main publication of this project has been published in the Lancet Respiratory Medicine in 2014. Further analysis has been performed at the induction of resistance by macrolides in collaboration with the Amphia Hospital and UMCU. The results of this study have been implemented in the European COPD guideline. We are now investigating the effects of macrolide treatment for more than one year. Also we perform research in the field of Bronchiectasis. The clinical impact of colonization and eradication of Pseudomonas aeruginosa has been investigated and recently published. A placebo-controlled randomized trial investigating the additional value of inhalation corticosteroids (ICS) in bronchiectasis started in March 2019 at the Erasmus MC. In this project we look at the clinical and laboratory effects of ICS on inflammation.
Key Publications
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, Pelle AJ, Hoogsteden HC, Aerts JG, van der Eerden MM. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014 May;2(5):361-8
The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre. Pieters A, Bakker M, Hoek RAS, Altenburg J, van Westreenen M, Aerts JGJV, van der Eerden MM. Eur Respir J. 2019 Apr 11;53(4). pii: 1802081. doi: 10.1183/13993003.02081-2018.
Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. Djamin RS, Bafadhel M, Uzun S, Russell REK, Ermens AAM, Kerstens R, Aerts JGJV, Pavord ID, van der Eerden MM. Respir Med. 2019 Jul - Aug;154:27-33. doi: 10.1016/j.rmed.2019.06.005
[Use of antibiotics for asthma and COPD exacerbation]. van der Eerden MM. Ned Tijdschr Geneeskd. 2019 Aug 22;163
